# Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis

> **NCT03598751** · PHASE3 · COMPLETED · sponsor: **Biocad** · enrollment: 194 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** BCD-085
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03598751
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-25
- **Primary completion:** 2019-06-26
- **Final completion:** 2022-08-31
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03598751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03598751, "Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03598751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*